Company Overview - LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people globally [3] Financial Results Announcement - The company will release its second quarter 2024 financial results on August 1, 2024, after market close [2] - A conference call is scheduled for 5:00 PM ET on the same day to discuss the results, business highlights, and company outlook [2] Access to Information - Access to the live call is available through online registration, and registrants will receive dial-in information and a PIN [4] - The audio webcast can be accessed live or via replay on the company's investor website [4]

Investment Thesis - LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a provider of medical devices for treating peripheral vascular disease, end-stage renal disease, and cardiovascular disease [5][30] - The company has demonstrated a 27% CAGR in market value and an 18% CAGR in dividend growth since 2011, indicating strong long-term performance [4][35] - Current valuation estimates range from $100 to $107 per share, supported by increasing economic profit and projected sales growth of 12.1% in FY'24 [15][20] Financial Performance - The company's market capitalization is approximately $1.85 billion, with 22 million shares outstanding, resulting in an EV/NOPAT multiple of 51.2x [8][18] - Economic profit increased from $3 million in FY'22 to $11 million in the trailing twelve months (TTM), reflecting improved operational efficiency [11][18] - NOPAT margins have improved to 18%, with capital turnover increasing to 0.95x, indicating better utilization of assets [11][35] Competitive Advantage - The market perceives LMAT's competitive advantage period (CAP) to be over 5 years, an increase from approximately 2 years in FY'22, suggesting enhanced growth potential [12][30] - The company has a strong focus on niche products with high switching costs, allowing it to maintain higher profit margins compared to industry averages [35][30] - International sales have shown significant growth, with a 44% increase in Q1 FY'24, positioning the company well for future expansion [35][30] Growth Catalysts - Management plans to expand its direct sales force to 150 representatives by the end of FY'24, which is expected to drive sales growth [27] - The company anticipates receiving multiple CE Marks for its products, which will facilitate entry into new markets and enhance sales [28] - Implementation of a new enterprise resource planning system is expected to improve operational efficiency and analytics, contributing to future growth [28] Valuation Insights - The current high multiples are justified by the company's strong fundamentals and growth prospects, with potential for further multiples expansion [20][19] - A 5% contraction in multiples still supports a valuation of approximately $90 per share, indicating a margin of safety [20][30] - The company has consistently generated free cash flow of $25–$35 million annually, reinforcing its financial stability [35][30]

Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. ...

BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufact ...

Most Powerful Force Impacting Stock Prices LeMaitre Vascular (LMAT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO ...

Exhibit 99.1 LeMaitre Q1 2024 Financial Results BURLINGTON, MA, May 2, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q1 2024 Financial Results On April 30, 2024, the Company's Board of Directors approved a quarterly dividend of $0.16/share of common stock. The dividend will be paid on May 30, 2024, to shareholders of record on May 16, 2024. Share Repurchase Program On Feb ...

BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the li ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State o ...

Exhibit 99.1 LeMaitre Q4 2023 Financial Results BURLINGTON, MA, February 27, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results Bovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1% ...